Please enable JavaScript to continue using this application.

Compare $AVBP vs $GLUE | Chartloom

Compare

$AVBP vs $GLUE

ArriVent BioPharma Inc · Monte Rosa Therapeutics Inc

AVBP

ArriVent BioPharma Inc

GLUE

Monte Rosa Therapeutics Inc

Compare $AVBP vs $GLUE

Comparing ArriVent BioPharma Inc and Monte Rosa Therapeutics Inc

AVBPArriVent BioPharma Inc

GLUEMonte Rosa Therapeutics Inc

AVBPArriVent BioPharma Inc

Market cap

$779M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

18.53x

Rev growth (TTM)

—

YTD performance

-19.6%

52W performance

-19.6%

FCF yield

-19.0%

GLUEMonte Rosa Therapeutics Inc

Market cap

$870M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.85x

Rev growth (TTM)

-83.9%

YTD performance

-32.7%

52W performance

33.6%

FCF yield

-3.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVBP

GLUE

Detailed metrics comparison

AVBP

ArriVent BioPharma Inc

GLUE

Monte Rosa Therapeutics Inc

Market Cap

AVBP$779M

GLUE$870M

Enterprise Value

AVBP$624M

GLUE$780M

Price

AVBP$16.73

GLUE$10.30

P/E Ratio

AVBPN/A

GLUEN/A

P/S Ratio

AVBP0.00x

GLUE30.29x

EV/Sales

AVBP0.00x

GLUE27.15x

EV/EBITDA

AVBP0.00x

GLUE47.84x

P/B Ratio

AVBP3.80x

GLUE1.84x

P/FCF Ratio

AVBPN/A

GLUEN/A

EV/FCF

AVBP-4.22x

GLUE-24.32x

PEG Ratio

AVBPN/A

GLUEN/A

Forward P/E (NTM)

AVBPN/A

GLUEN/A

Forward P/S (NTM)

AVBP18.53x

GLUE21.85x

Revenue (TTM)

AVBP$0

GLUE$29M

Revenue Growth (YoY)

AVBPN/A

GLUE-83.9%

Forward Rev Growth

AVBP244.4%

GLUE-58.1%

Gross Margin (TTM)

AVBP0.0%

GLUE0.0%

Operating Margin (TTM)

AVBP0.0%

GLUE0.0%

EBITDA Margin (TTM)

AVBP0.0%

GLUE-604.8%

Net Margin (TTM)

AVBP0.0%

GLUE-560.9%

FCF Margin (TTM)

AVBPN/A

GLUE-111.7%

Net Income (TTM)

AVBP$-164M

GLUE$-161M

FCF (TTM)

AVBP$-148M

GLUE$-32M

EPS (TTM)

AVBP-$3.44

GLUE-$1.59

ROE (TTM)

AVBP-5026.0%

GLUE-4331.0%

ROA (TTM)

AVBP-4666.0%

GLUE-2759.0%

ROIC (TTM)

AVBP-5026.0%

GLUE-4331.0%

Cash

AVBP$155M

GLUE$90M

Debt

AVBP$0

GLUE$0

Net Cash/Debt

AVBP$155M

GLUE$90M

Current Ratio (TTM)

AVBP14.16x

GLUE10.58x

Quick Ratio (TTM)

AVBP14.14x

GLUE10.49x

Debt/Equity (TTM)

AVBP0.00x

GLUE0.00x

Debt/Assets (TTM)

AVBP0.0%

GLUE0.0%

Interest Coverage (TTM)

AVBPN/A

GLUEN/A

Net Debt/EBITDA (TTM)

AVBP0.00x

GLUE0.00x

Beta

AVBP1.42

GLUE1.34

52W Performance

AVBP-19.6%

GLUE33.6%

YTD Performance

AVBP-19.6%

GLUE-32.7%

% from 52W High

AVBP-53.3%

GLUE-60.0%

% from 52W Low

AVBP47.3%

GLUE34.7%

Asset Turnover (TTM)

AVBP0.00x

GLUE0.05x

FCF Yield (TTM)

AVBP-19.0%

GLUE-3.7%

Earnings Yield (TTM)

AVBP-21.0%

GLUE-18.5%

Dividend Yield (TTM)

AVBPN/A

GLUEN/A

Rule of 40

AVBP0.0

GLUE-195.5

EV/GP/RG

AVBPN/A

GLUEN/A

Ticker research

View AVBP research View GLUE research

Metric	AVBP ArriVent BioPharma Inc	GLUE Monte Rosa Therapeutics Inc
Market & Valuation
Market Cap	$779M	$870M
Enterprise Value	$624M	$780M
Price	$16.73	$10.30
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	30.29x
EV/Sales	0.00x	27.15x
EV/EBITDA	0.00x	47.84x
P/B Ratio	3.80x	1.84x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.22x	-24.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	18.53x	21.85x
Revenue & Growth
Revenue (TTM)	$0	$29M
Revenue Growth (YoY)	N/A	-83.9%
Forward Rev Growth	244.4%	-58.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-604.8%
Net Margin (TTM)	0.0%	-560.9%
FCF Margin (TTM)	N/A	-111.7%
Net Income (TTM)	$-164M	$-161M
FCF (TTM)	$-148M	$-32M
EPS (TTM)	-$3.44	-$1.59
ROE (TTM)	-5026.0%	-4331.0%
ROA (TTM)	-4666.0%	-2759.0%
ROIC (TTM)	-5026.0%	-4331.0%
Financial Health
Cash	$155M	$90M
Debt	$0	$0
Net Cash/Debt	$155M	$90M
Current Ratio (TTM)	14.16x	10.58x
Quick Ratio (TTM)	14.14x	10.49x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.42	1.34
52W Performance	-19.6%	33.6%
YTD Performance	-19.6%	-32.7%
% from 52W High	-53.3%	-60.0%
% from 52W Low	47.3%	34.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.05x
FCF Yield (TTM)	-19.0%	-3.7%
Earnings Yield (TTM)	-21.0%	-18.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-195.5
EV/GP/RG	N/A	N/A
Ticker research	View AVBP research	View GLUE research

Valuation

P/S Ratio

AVBP

0.00x

GLUE

30.29x

EV/FCF

GLUE

-24.32x

AVBP

-4.22x

Growth & revenue

Revenue Growth TTM

GLUE

-83.9%

Forward Revenue Growth

AVBP

244.4%

GLUE

-58.1%

Profitability & performance

Gross Margin

AVBP

0.0%

GLUE

0.0%

ROE

GLUE

-4331.0%

AVBP

-5026.0%

FCF Yield %

GLUE

-3.7%

AVBP

-19.0%

52-Week Performance

GLUE

33.6%

AVBP

-19.6%

Detailed metrics comparison

AVBP

ArriVent BioPharma Inc

GLUE

Monte Rosa Therapeutics Inc

Market Cap

AVBP$779M

GLUE$870M

Enterprise Value

AVBP$624M

GLUE$780M

Price

AVBP$16.73

GLUE$10.30

P/E Ratio

AVBPN/A

GLUEN/A

P/S Ratio

AVBP0.00x

GLUE30.29x

EV/Sales

AVBP0.00x

GLUE27.15x

EV/EBITDA

AVBP0.00x

GLUE47.84x

P/B Ratio

AVBP3.80x

GLUE1.84x

P/FCF Ratio

AVBPN/A

GLUEN/A

EV/FCF

AVBP-4.22x

GLUE-24.32x

PEG Ratio

AVBPN/A

GLUEN/A

Forward P/E (NTM)

AVBPN/A

GLUEN/A

Forward P/S (NTM)

AVBP18.53x

GLUE21.85x

Revenue (TTM)

AVBP$0

GLUE$29M

Revenue Growth (YoY)

AVBPN/A

GLUE-83.9%

Forward Rev Growth

AVBP244.4%

GLUE-58.1%

Gross Margin (TTM)

AVBP0.0%

GLUE0.0%

Operating Margin (TTM)

AVBP0.0%

GLUE0.0%

EBITDA Margin (TTM)

AVBP0.0%

GLUE-604.8%

Net Margin (TTM)

AVBP0.0%

GLUE-560.9%

FCF Margin (TTM)

AVBPN/A

GLUE-111.7%

Net Income (TTM)

AVBP$-164M

GLUE$-161M

FCF (TTM)

AVBP$-148M

GLUE$-32M

EPS (TTM)

AVBP-$3.44

GLUE-$1.59

ROE (TTM)

AVBP-5026.0%

GLUE-4331.0%

ROA (TTM)

AVBP-4666.0%

GLUE-2759.0%

ROIC (TTM)

AVBP-5026.0%

GLUE-4331.0%

Cash

AVBP$155M

GLUE$90M

Debt

AVBP$0

GLUE$0

Net Cash/Debt

AVBP$155M

GLUE$90M

Current Ratio (TTM)

AVBP14.16x

GLUE10.58x

Quick Ratio (TTM)

AVBP14.14x

GLUE10.49x

Debt/Equity (TTM)

AVBP0.00x

GLUE0.00x

Debt/Assets (TTM)

AVBP0.0%

GLUE0.0%

Interest Coverage (TTM)

AVBPN/A

GLUEN/A

Net Debt/EBITDA (TTM)

AVBP0.00x

GLUE0.00x

Beta

AVBP1.42

GLUE1.34

52W Performance

AVBP-19.6%

GLUE33.6%

YTD Performance

AVBP-19.6%

GLUE-32.7%

% from 52W High

AVBP-53.3%

GLUE-60.0%

% from 52W Low

AVBP47.3%

GLUE34.7%

Asset Turnover (TTM)

AVBP0.00x

GLUE0.05x

FCF Yield (TTM)

AVBP-19.0%

GLUE-3.7%

Earnings Yield (TTM)

AVBP-21.0%

GLUE-18.5%

Dividend Yield (TTM)

AVBPN/A

GLUEN/A

Rule of 40

AVBP0.0

GLUE-195.5

EV/GP/RG

AVBPN/A

GLUEN/A

Ticker research

View AVBP research View GLUE research

Metric	AVBP ArriVent BioPharma Inc	GLUE Monte Rosa Therapeutics Inc
Market & Valuation
Market Cap	$779M	$870M
Enterprise Value	$624M	$780M
Price	$16.73	$10.30
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	30.29x
EV/Sales	0.00x	27.15x
EV/EBITDA	0.00x	47.84x
P/B Ratio	3.80x	1.84x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.22x	-24.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	18.53x	21.85x
Revenue & Growth
Revenue (TTM)	$0	$29M
Revenue Growth (YoY)	N/A	-83.9%
Forward Rev Growth	244.4%	-58.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-604.8%
Net Margin (TTM)	0.0%	-560.9%
FCF Margin (TTM)	N/A	-111.7%
Net Income (TTM)	$-164M	$-161M
FCF (TTM)	$-148M	$-32M
EPS (TTM)	-$3.44	-$1.59
ROE (TTM)	-5026.0%	-4331.0%
ROA (TTM)	-4666.0%	-2759.0%
ROIC (TTM)	-5026.0%	-4331.0%
Financial Health
Cash	$155M	$90M
Debt	$0	$0
Net Cash/Debt	$155M	$90M
Current Ratio (TTM)	14.16x	10.58x
Quick Ratio (TTM)	14.14x	10.49x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.42	1.34
52W Performance	-19.6%	33.6%
YTD Performance	-19.6%	-32.7%
% from 52W High	-53.3%	-60.0%
% from 52W Low	47.3%	34.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.05x
FCF Yield (TTM)	-19.0%	-3.7%
Earnings Yield (TTM)	-21.0%	-18.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-195.5
EV/GP/RG	N/A	N/A
Ticker research	View AVBP research	View GLUE research